Vinh Phuc Pharmaceutical Joint Stock Company

What Vinh Phuc Pharmaceutical Joint Stock Company does

Vinh Phuc Pharmaceutical Joint Stock Company (VINPHACO) is a Vietnam-based pharmaceutical manufacturer founded in 1959, originally a state-owned enterprise and now operating as a joint stock company. The company operates a GMP-WHO certified manufacturing facility in Phu Tho Province with an executive office in Hanoi, employing between 501 and 1,000 people. It produces more than 300 pharmaceutical products spanning 25 treatment groups, with specialty capabilities in lyophilization and Blow-Fill-Seal (BFS) aseptic manufacturing, alongside R&D conducted by a team of over 40 specialists.

The company's go-to-market operates through two channels: ETC (hospital tender) and OTC (pharmacy retail), with sales coverage across all 63 provinces of Vietnam via approximately 100 sales representatives. Internationally, VINPHACO exports to more than 20 countries with active expansion into the Philippines (following June 2025 FDA GMP certification), Africa, South America, and the broader ASEAN region. Supporting technology infrastructure includes SAP for enterprise management, Dassault Systèmes 3DEXPERIENCE (deployed in partnership with Kami Manufacturing Technology in April 2025) for product lifecycle and manufacturing design, and big data analytics applied to quality control.

Revenue is generated through product sales — B2B via government hospital procurement contracts and B2C via pharmacy distribution — with the larger share of value capture sitting in the manufactured finished-dose product rather than distribution. The 2025 strategic plan is organized around a "Breakthrough in Revenue and Efficiency" theme, with a stated 23% top-line growth target, multi-product launches, and digital transformation. The company has held the High-Quality Vietnamese Goods certification for 10 consecutive years and has been recognized as a Vietnam National Brand, supporting its institutional positioning with both regulators and hospital buyers.

Name

Vinh Phuc Pharmaceutical Joint Stock Company

Legal name

Vinh Phuc Pharmaceutical Joint Stock Company

Website

https://vinphaco.net

Company type

Private

Founded year

1959

Operating status

Operating

Headcount range

501–1,000 employees

Short description

VINPHACO is a Vietnam-based GMP-WHO certified pharmaceutical manufacturer founded in 1959, producing 300+ products across 25 treatment groups for government hospitals and pharmacy retail domestically and exporting to 20+ countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Specialty Pharmaceutical Distributors (HLAIAJAB), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic pharmaceutical manufacturing
• Sterile injectable production
• Lyophilized injectable drugs
• GMP certified manufacturing
• Pharmaceutical contract manufacturing

Headquarters

HQ city

Vinh

HQ country

Vietnam

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and selling over 300 pharmaceutical products across 25 treatment groups to healthcare facilities throughout Vietnam and international markets
2. Contract Manufacturing: Providing contract manufacturing services for pharmaceutical products under GMP-WHO standards to international clients
3. Export/Distribution: Export of pharmaceutical products to over 20 countries worldwide with dedicated service and high-quality products meeting GMP standards of multiple nations

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

VINPHACO manufactures and supplies over 300 pharmaceutical products across 25 treatment groups, with a specialty in sterile injectable drugs (including lyophilized powders and BFS aseptic products), tablets, capsules, eye drops, and health supplements produced under GMP-WHO standards. The company sells both branded generic drugs (ETC prescription products to hospitals and OTC products through retail pharmacies) and provides contract/OEM manufacturing services to international pharmaceutical clients, with exports spanning 20+ countries.

Product overview

Vinphaco is a pharmaceutical manufacturer producing over 300 products across multiple therapeutic categories including Emergency and Stroke, Neurology, Cardiovascular & Diabetes, Gastroenterology, Anesthesia & Obstetrics, Antibiotics, and Corticoid/NSAIDs. The company's product portfolio includes injectable solutions (BFS lines, freeze-drying technology), tablets, eye drops, and dietary supplements. Key product lines include neurological injections, endocrine system injections, inhalation solutions, and hemostatic injections. Vinphaco provides both branded pharmaceutical products and contract manufacturing (OEM) services for international clients.

Differentiator

Problem solved

Functional benefit

Products and services

• Emergency and Stroke Product Line

Quantifiable outcome

• Products exported to 20+ countries worldwide
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• Kami Manufacturing Technology Joint Stock CompanycoreTechnology or Integration · 23 April 2025Strategic cooperation signing on April 23, 2025 at Forum on Building Local Digital Economy Based on High-Tech Supply Chain. Partnership deploys Dassault Systèmes 3DEXPERIENCE platform to build smart pharmaceutical enterprise model enabling end-to-end digitalization of production, design, operations, and supply chain management. Includes joint development of digital human resources and technology demonstration centers.
• Vietnam Medical AssociationcoreStrategic or Co-development Partner · 19 April 2025Collaboration with Ministry of Health to organize Hospital Management Conference 2025 under theme 'Updates on Health Insurance Policies and Drug Bidding Regulations'. Conference brought together over 120 delegates including senior Ministry of Health representatives. Platform for connecting medical system with latest policy changes, supporting healthcare sector development.
• Ministry of Health (Vietnam)coreStrategic or Co-development Partner · 19 April 2025Partnership in organizing Hospital Management Conference 2025 with Vietnam Medical Association. Senior representatives from Department of Medical Services Administration, Department of Health Insurance, and Department of Planning and Finance participated, providing updates on health insurance policies and drug bidding regulations.
• China Pharmaceutical Equipment AssociationcoreStrategic or Co-development Partner · 9 April 2025Delegation visit on April 9, 2025 to Vinphaco headquarters marking closer cooperation and opening opportunities for technology transfer, production modernization, and advancement of Vietnam's pharmaceutical industry. Association has 500+ member companies specializing in API equipment, formulation machinery, water/air treatment systems, and testing equipment. Exchange of views on regional pharmaceutical market trends and collaboration in technology transfer and professional training.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Pymepharco JSC: Vietnamese pharmaceutical company producing finished drugs (sterile injectables, tablets, capsules) with EU-GMP certified facilities and export presence. Directly comparable to VINPHACO in sterile injectable manufacturing, GMP standards, and domestic + export business model.
• Bidiphar JSC: Vietnamese pharmaceutical manufacturer producing finished dosage forms including injectables, tablets, and capsules, with hospital and retail distribution. Comparable to VINPHACO in generic pharma manufacturing, hospital-channel distribution, and state-enterprise heritage.
• Imexpharm Pharmaceutical JSC: Vietnamese pharmaceutical manufacturer specializing in finished dosage forms (tablets, capsules, injectables) with GMP-compliant facilities and hospital-channel distribution. Comparable to VINPHACO in generic pharma manufacturing, steriles, and hospital tender business.
• Traphaco JSC: Leading Vietnamese pharmaceutical manufacturer with a large portfolio of generic drugs, OTC products, and traditional medicines, distributing nationally to hospitals and pharmacies. Directly comparable to VINPHACO as a long-established Vietnamese pharma manufacturer with similar ETC/OTC channel mix.
• Hau Giang Pharmaceutical JSC (DHG Pharma): One of Vietnam's largest domestic pharmaceutical manufacturers, producing generic and specialty pharmaceutical products including tablets, capsules, and injectables across a broad therapeutic portfolio. Directly comparable to VINPHACO in product breadth, GMP-certified manufacturing, and domestic hospital + retail distribution.
• OPC Pharmaceutical JSC: Vietnamese pharmaceutical company producing generic drugs and OTC products, including injectables and tablets, with broad domestic distribution. Comparable to VINPHACO as a long-standing domestic pharma manufacturer with similar ETC/OTC channel coverage.
• Mekophar Chemical Pharmaceutical JSC: Vietnamese pharmaceutical manufacturer producing generic drugs, antibiotics, and healthcare products with domestic distribution and selected exports. Comparable to VINPHACO as a domestic GMP-certified pharma manufacturer with OTC and ETC channel presence.

Broad incumbents

• Sanofi Vietnam: Multinational pharmaceutical company with a significant Vietnamese footprint producing and distributing branded prescription and OTC drugs. Comparable to VINPHACO as a hospital-and-pharmacy pharmaceutical supplier in Vietnam, but operates as a multinational affiliate with broader global portfolio rather than a domestic generic specialist.
• Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer producing finished dosage forms including sterile injectables, with extensive global export distribution including semi-regulated markets. Comparable to VINPHACO in generic injectable manufacturing, contract manufacturing services, and export to emerging markets — a key competitive benchmark for international expansion.

Regional players

• Vietnam Pharmaceutical Corporation (Vinapharm): State-owned umbrella holding for several Vietnamese pharmaceutical manufacturers producing generics and distributing nationally. Comparable to VINPHACO as a domestic pharmaceutical producer with hospital-channel distribution and a similar state-enterprise heritage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/dpvinphaco
• LinkedInlinkedin.com/company/vinphaco-pharmaceutical

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vinh Phuc Pharmaceutical Joint Stock Company